In the recent clinical data, we present here and previously published [50–53], toripalimab in combination with chemotherapy conferred an overall survival benefit over chemotherapy alone in NPC, NSCLC and ESCC patients, irrespective of their PD-L1 status in subgroup analyses. Here, CD274 is linked to non-small cell lung carcinoma.